| Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era G Goyal, ML Heaney, M Collin, F Cohen-Aubart, A Vaglio, BH Durham, ... Blood, The Journal of the American Society of Hematology 135 (22), 1929-1945, 2020 | 250 | 2020 |
| A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs D Rea, MJ Mauro, C Boquimpani, Y Minami, E Lomaia, S Voloshin, ... Blood, The Journal of the American Society of Hematology 138 (21), 2031-2041, 2021 | 201 | 2021 |
| Hypertensive crisis: clinical–epidemiological profile JF Vilela-Martin, RO Vaz-de-Melo, CH Kuniyoshi, ANR Abdo, ... Hypertension Research 34 (3), 367-371, 2011 | 146 | 2011 |
| BRAF V600E mutation detected in a case of Rosai-Dorfman disease G Fatobene, J Haroche, Z Hélias-Rodzwicz, F Charlotte, V Taly, ... Haematologica 103 (8), e377, 2018 | 52 | 2018 |
| Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3 … JP Laubach, F Schjesvold, M Mariz, MA Dimopoulos, E Lech-Maranda, ... The Lancet Oncology 22 (1), 142-154, 2021 | 50 | 2021 |
| Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL A Hochhaus, D Réa, C Boquimpani, Y Minami, JE Cortes, TP Hughes, ... Leukemia 37 (3), 617-626, 2023 | 45 | 2023 |
| How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation GF Perini, T Fischer, RD Gaiolla, TB Rocha, M Bellesso, LLC Teixeira, ... Hematology, Transfusion and Cell Therapy 42 (2), 103-110, 2020 | 42 | 2020 |
| Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with … A Hochhaus, C Boquimpani, D Rea, Y Minami, E Lomaia, S Voloshin, ... Blood 136, LBA-4, 2020 | 33 | 2020 |
| Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid … MJ Mauro, Y Minami, D Rea, A Hochhaus, E Lomaia, S Voloshin, ... Blood 138, 310, 2021 | 23 | 2021 |
| Indeterminate cell histiocytosis successfully treated with phototherapy MCN Zerbini, MN Sotto, FPF de Campos, ANR Abdo, J Pereira, ... Autopsy & Case Reports 6 (2), 33, 2016 | 17 | 2016 |
| Diffuse large B-cell lymphoma presenting in the leukemic phase PP Pires, MY Kanegae, J Rays, M Catania, FR Lima, TR Noronha, ... Autopsy & case reports 6 (1), 41, 2016 | 13 | 2016 |
| Cardiovascular manifestations of Erdheim-Chester's disease: a case series IBSS Costa, ANR Abdo, CS Bittar, SMR Fonseca, ASHT Moraes, ... Arquivos Brasileiros de Cardiologia 111, 852-855, 2018 | 10 | 2018 |
| Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment … FS Seguro, CMPDC Silva, CMB Moura, M Conchon, L Fogliatto, ... Hematology, Transfusion and Cell Therapy 43, 191-200, 2021 | 9 | 2021 |
| MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: results of a prospective trial FS Seguro, FVR Maciel, FM Santos, ANR Abdo, TDM Pereira, L Nardinelli, ... Leukemia Research 101, 106516, 2021 | 7 | 2021 |
| S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER≥ 2 PRIOR TYROSINE … D Rea, A Hochhaus, MJ Mauro, Y Minami, E Lomaia, S Voloshin, ... HemaSphere 6, 56-57, 2022 | 6 | 2022 |
| Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for … CM Boquimpani, ANR Abdo, DP Martins, LBA Lima, MS Torriani, I Bendit Hematology, Transfusion and Cell Therapy 43, 50-57, 2021 | 6 | 2021 |
| Cardiac tamponade as the first manifestation of Erdheim-Chester disease IBSS Costa, FAS Costa, CS Bittar, SI Rizk, ANR Abdo, SAC Siqueira, ... Cardio Oncology 2 (2), 324-328, 2020 | 6 | 2020 |
| Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH). How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian … GF Perini, T Fischer, RD Gaiolla, TB Rocha, M Bellesso, LLC Teixeira, ... Hematol Transfus Cell Ther 42 (2), 103-110, 2020 | 6 | 2020 |
| Duration of major molecular response and discontinuation in deep molecular response (MR4. 5) were associated with longer treatment-free survival after imatinib discontinuation … KB Pagnano, FS Seguro, EC Miranda, ABP Lopes, A Abdo, MT Delamain, ... Blood 134, 1655, 2019 | 6 | 2019 |
| Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with … M Mauro, Y Minami, A Hochhaus, E Lomaia, S Voloshin, A Turkina, ... Blood 142, 4536, 2023 | 2 | 2023 |
